We are live on ! Find out more
CCP

Clough Capital Partners Portfolio holdings

AUM $1.23B
1-Year Est. Return 51.32%
This Fund
S&P 500
This Quarter Est. Return
+11.66%
1 Year Est. Return
+51.32%
3 Year Est. Return
+175.14%
5 Year Est. Return
+243.7%
10 Year Est. Return
+1,533.05%
AUM
$994M
AUM Growth
+$66M
Cap. Flow
-$11.6M
Cap. Flow %
-1.17%
Top 10 Hldgs %
26.27%
Holding
195
New
31
Increased
46
Reduced
57
Closed
20

Top Sells

Rank Stock Value
1
NOC icon
Northrop Grumman
NOC
+$17.5M
2
AMT icon
American Tower
AMT
+$16.6M
3
TMUS icon
T-Mobile US
TMUS
+$12.3M
4
TSM icon
TSMC
TSM
+$12.1M
5
LEGN icon
Legend Biotech
LEGN
+$10.5M

Sector Composition

Rank Sector Weight
1 Healthcare 21.52%
2 Consumer Discretionary 14.91%
3 Technology 13.93%
4 Miscellaneous 10.97%
5 Financials 10.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MTB icon
51
M&T Bank
MTB
$34B
$7.19M 0.72%
58,100
+19,270
+50% +$2.33M
CMA
52
DELISTED
Comerica
CMA
$7.15M 0.72%
168,700
+59,600
+55% +$2.41M
VCYT icon
53
Veracyte
VCYT
$3.23B
$7.04M 0.71%
276,260
-63,718
-19% -$1.54M
ACN icon
54
Accenture
ACN
$118B
$6.26M 0.63%
20,300
EXC icon
55
Exelon
EXC
$43.5B
$5.9M 0.59%
144,800
KEY icon
56
KeyCorp
KEY
$23.2B
$5.64M 0.57%
610,600
+231,300
+61% +$2.41M
REGN icon
57
Regeneron Pharmaceuticals
REGN
$79.7B
$5.61M 0.56%
+7,805
New +$6.02M
MEGI
58
NYLIM CBRE Global Infrastructure Megatrends Term Fund
MEGI
$741M
$5.45M 0.55%
397,858
-15,000
-4% -$212K
V icon
59
Visa
V
$701B
$5.39M 0.54%
22,695
-28,985
-56% -$6.63M
TSVT
60
DELISTED
2seventy bio
TSVT
$5.35M 0.54%
529,110
+280,500
+113% +$2.97M
LIN icon
61
Linde
LIN
$213B
$5.3M 0.53%
13,900
ROIV icon
62
Roivant Sciences
ROIV
$28.5B
$5.12M 0.51%
+507,500
New +$4.54M
LNG icon
63
Cheniere Energy
LNG
$56B
$5.11M 0.51%
33,565
-1,440
-4% -$213K
FCX icon
64
Freeport-McMoran
FCX
$99.6B
$5.04M 0.51%
+125,900
New +$4.8M
MET icon
65
MetLife
MET
$62.4B
$4.91M 0.49%
+86,900
New +$4.82M
BXSL icon
66
Blackstone Secured Lending
BXSL
$5.78B
$4.88M 0.49%
178,500
-44,200
-20% -$1.14M
BMEZ icon
67
BlackRock Health Sciences Trust II
BMEZ
$1B
$4.76M 0.48%
289,736
+46,600
+19% +$759K
ASND icon
68
Ascendis Pharma A/S
ASND
$15.8B
$4.57M 0.46%
+51,200
New +$4.46M
BSTZ icon
69
BlackRock Science and Technology Term Trust
BSTZ
$1.91B
$4.49M 0.45%
247,940
+24,340
+11% +$419K
DUK icon
70
Duke Energy
DUK
$91.8B
$4.31M 0.43%
48,000
-12,000
-20% -$1.13M
HALO icon
71
Halozyme
HALO
$12.1B
$4.28M 0.43%
118,600
-2,700
-2% -$92.1K
BMRN icon
72
BioMarin Pharmaceuticals
BMRN
$12.5B
$4.16M 0.42%
+47,970
New +$4.51M
TCOM icon
73
Trip.com Group
TCOM
$24.7B
$4.08M 0.41%
+116,500
New +$4.05M
SLB icon
74
SLB Ltd
SLB
$80.4B
$4.01M 0.4%
81,630
-3,700
-4% -$176K
CSCO icon
75
Cisco
CSCO
$434B
$4M 0.4%
77,300
-61,100
-44% -$3.01M

Similar funds

Clough Capital Partners's Q2 2023 Portfolio in Review

As of Q2 2023, Clough Capital Partners held 195 positions worth $994M, up 7.1% from $928M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Clough Capital Partners's Q2 2023 filing shows 31 new, 46 increased, 57 reduced and 20 closed positions. Its largest new stake was DraftKings: 786,100 shares worth $20.9M. The largest sale was Northrop Grumman, an estimated $17.5M.

By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 23% a quarter earlier, followed by Consumer Discretionary and Technology.

  • Clough Capital Partners's largest Q2 2023 buy was DraftKings: 786,100 shares worth $20.9M.
  • Clough Capital Partners added most to Alphabet (Google) Class C in Q2 2023, an estimated $21.5M increase.
  • Clough Capital Partners's biggest Q2 2023 reduction was Northrop Grumman, cutting an estimated $17.5M.
  • Clough Capital Partners fully exited American Tower in Q2 2023, selling an estimated $16.6M.
  • Clough Capital Partners's ten largest holdings make up 26% of its $994M portfolio in Q2 2023.
  • Clough Capital Partners opened 31 new positions and closed 20 in Q2 2023.
  • Clough Capital Partners's portfolio value rose 7.1% quarter-over-quarter to $994M.

Based on Clough Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.